- Home
- USEA vs NERV Comparison
USEA vs NERV Comparison
Compare USEA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | NERV |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 14.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | USEA | NERV |
|---|---|---|
| Price | $1.84 | $3.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 76.3K | ★ 80.1K |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,025,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.15 |
| 52 Week High | $2.00 | $12.46 |
Technical Indicators
Market Signals| Indicator | USEA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 50.95 |
| Support Level | $1.59 | $3.76 |
| Resistance Level | $1.76 | $4.21 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 92.19 | 43.70 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of five dry bulk vessels, comprising two Kamsarmax and three Panamax vessels with an aggregate cargo-carrying capacity of approximately 396,297 dwt.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.